复发性/耐火性CLL: allo-SCT,CAR-T和T细胞参与者的作用
Arnon P Kater1, Tanya Siddiqi2
1Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
Hematology. American Society of Hematology. Education Program
|December 7, 2024
概括
新型免疫疗法,包括CAR T细胞疗法和双特异性抗体,为慢性淋巴细胞白血病 (CLL) 患者提供了新的希望,这些患者对当前治疗有抗性. 研究重点是克服T细胞功能障碍,以获得更持久,更有效的CLL治疗.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 血液学 血液学 血液学
背景情况:
- 慢性淋巴细胞白血病 (CLL) 患者耐受布鲁顿氨酸激酶 (BTK) 和B细胞/CLL淋巴瘤2 (BCL2) 抑制剂的治疗选择有限.
- 现有的疗法,如全源干细胞移植,具有显著的局限性,包括高死亡率和移植对宿主疾病.
研究的目的:
- 探索针对复发性/耐药性CLL的新型免疫治疗策略.
- 解决在具有挑战性的CLL病例中对有效和持久治疗的未满足需求.
主要方法:
- 审查新兴免疫疗法,如化学抗原受体 (CAR) T 细胞疗法和双特异性抗体.
- 研究克服CLL患者T细胞功能障碍的策略.
主要成果:
- 早期临床试验表明,CAR T细胞疗法可以在重度预治疗的CLL患者中诱导持久缓解和高反应率.
- 双特异性抗体在向CLL细胞方面表现出有希望的临床前和早期临床疗效.
- 基于T细胞治疗CLL的T细胞功能障碍是一个关键挑战.
结论:
- 免疫疗法,特别是CAR T细胞和双特异性抗体,代表了耐火性CLL的一个有希望的前沿.
- 增强T细胞功能的策略对于改善CLL患者的治疗结果至关重要.
- 组合疗法和新型CAR设计为更有效和可持续的CLL治疗提供了潜力.
更多相关视频
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
3.3K
09:01Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
290
相关概念视频
T Cell Activation and Clonal Selection
658
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
658
T Cell Types and Functions
951
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
951
